Robich Michael P, Chu Louis M, Oyamada Shizu, Sodha Neel R, Sellke Frank W
Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert School of Medicine, Brown University, Providence, RI 02905, USA.
Expert Rev Cardiovasc Ther. 2011 Nov;9(11):1469-79. doi: 10.1586/erc.11.148.
A significant percentage of patients have coronary artery disease that is too advanced or diffuse for percutaneous or surgical intervention. Therapeutic angiogenesis is a treatment modality to induce vessel formation that is being developed for patients with advanced coronary disease not amenable to currently available interventions. A number of approaches to induce coronary collateralization are being developed. These include gene, protein, cellular and miRNA modalities, each of which have advantages and disadvantages. At this time, no modality has emerged as the single clear choice, and combination therapies may provide synergistic benefits. However, there have been a number of recent studies advancing our knowledge as to how we can refine procollateralizing treatments. In this article, we will examine some recent successes and future obstacles in the effort to bring therapeutic angiogenesis to patients.
相当大比例的患者患有冠状动脉疾病，病情过于严重或病变过于弥漫，无法进行经皮或外科干预。治疗性血管生成是一种诱导血管形成的治疗方式，正在为那些不适合现有干预措施的晚期冠状动脉疾病患者研发。目前正在开发多种诱导冠状动脉侧支循环形成的方法。这些方法包括基因、蛋白质、细胞和微小RNA方式，每种方式都有其优缺点。目前，没有一种方式成为唯一明确的选择，联合治疗可能会带来协同效益。然而，最近有许多研究增进了我们对如何优化促侧支循环治疗的认识。在本文中，我们将探讨在将治疗性血管生成应用于患者的努力中取得的一些近期成功以及未来面临的障碍。
